PRNewswire

Grant to support IND-enabling toxicology and Phase 1/1b development of novel cardiac-safe ibogaine analog, GM-3009 NEW YORK, March 14, 2024 /PRNewswire/ — Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for mental

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: